Medical Cannabis & Drug Interactions: Peer-Reviewed Research Consensus
Overview
The research base for medical cannabis & drug interactions includes 1691 peer-reviewed studies spanning 1975–2026. Of these, 142 provide strong evidence, including 36 meta-analyses and 141 randomized controlled trials. Key findings with strong support include: meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects, and meta-analysis of 11 rcts finding selective cannabinoids provide a small but significant reduction in neuropathic pain (-0. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.
What the Research Shows
Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.
Meta-analysis of 30 trials found cannabinoids significantly outperformed older anti-nausea drugs for chemotherapy, with nearly half of 1,138 patients preferring cannabinoids despite more side effects
Strong EvidenceMeta-analysis of 11 RCTs finding selective cannabinoids provide a small but significant reduction in neuropathic pain (-0
Strong EvidenceMeta-analysis of 550 patients found CBD reduced seizures by ~20 percentage points in severe childhood epilepsies
Strong EvidenceWhere Scientists Disagree
Areas where research shows conflicting results or ongoing scientific debate.
In a landmark NEJM trial, oral THC prevented chemotherapy vomiting in 80% of completed courses versus 0% for placebo, with no vomiting during subjective highs
Moderate EvidenceA 1978 medical review identified cannabis as promising for glaucoma and asthma but flagged cardiovascular risks during exercise and preliminary concerns about lung and immune effects
Moderate EvidenceA 1981 critical review found THC showed promise against chemotherapy nausea but identified significant gaps in safety and pharmacological knowledge
Moderate EvidenceData from 120 subjects showed cannabis tolerance develops and fades quickly, while withdrawal symptoms including insomnia, irritability, and tremor appeared after as few as 7 days of use
Moderate EvidenceWhat We Still Don't Know
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Evidence Breakdown
Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.
Key Studies
The most impactful research in this area.
Nearly 29% of North Americans have tried CBD, about double the rate in Europe
Despite the explosive growth of the CBD market, no prior systematic assessment of how many people actually use CBD existed. These numbers provide a baseline for tracking trends as regulations and products evolve.
Cannabis products with THC showed small pain improvements with significant side effects, while CBD alone did not help
This is the most current synthesis of cannabis for pain, showing benefits are small and limited to THC products while CBD alone does not help.
Meta-analysis found cannabis use disorder linked to more complications and higher costs after hip and knee replacements
Joint replacement is one of the most common elective surgeries. With cannabis use disorder increasing alongside legalization, this meta-analysis quantifies the specific complications orthopedic surgeons should watch for and discuss with patients.
Cannabinoid Medicines Are Generally Safe for Older Adults, With Dose-Dependent Side Effects
Older adults are the fastest-growing demographic of cannabinoid medicine users, yet most safety data comes from younger populations. This meta-analysis specifically addresses the 50+ age group, providing age-appropriate safety data for clinical decision-making.
Major meta-analysis of 152 RCTs finds cannabinoid effectiveness varies dramatically by specific drug and condition
By analyzing cannabinoid medications separately rather than lumping them together, this study reveals that the question "does cannabis work?" is misleading. The answer depends entirely on which cannabinoid and which condition.
Meta-analysis confirmed CBD reduces seizures by 33% in treatment-resistant epilepsy
This meta-analysis provides the strongest quantitative evidence to date supporting CBD as an add-on treatment for three of the most difficult-to-treat pediatric epilepsy syndromes.
Research Timeline
How our understanding of this topic has evolved.
Pre-2000
37 studies published. Includes 8 RCTs, 1 strong-evidence studies.
2000–2009
118 studies published. Includes 1 meta-analyses, 21 RCTs, 15 strong-evidence studies.
2010–2014
130 studies published. Includes 23 RCTs, 13 strong-evidence studies.
2015–2019
379 studies published. Includes 7 meta-analyses, 14 RCTs, 37 strong-evidence studies.
2020–present
1027 studies published. Includes 28 meta-analyses, 75 RCTs, 76 strong-evidence studies.
About This Consensus
This consensus synthesizes 1691 peer-reviewed studies: 36 meta-analyses (2%), 141 randomized controlled trials (8%), 419 observational studies (25%), 594 reviews (35%), 64 case studies (4%), 437 other study types (26%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
This page synthesizes findings from 1,691 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.
Read our guide: Medical Cannabis & Drug Interactions →